AMRX Q1 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$695M+5.5% YoY

Gross Profit

$256M36.8% margin

Operating Income

$100M14.4% margin

Net Income

$12M1.8% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

-4.8%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

-$11M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$3.4B

Stockholders' Equity

-$132M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$695M	$659M	+5.5%
Gross Profit	$256M	$238M	+7.5%
Operating Income	$100M	-$11M	+1033.8%
Net Income	$12M	-$92M	+113.3%

Revenue Segments

Amneal Specialty Pharma Segment

$108M50%

Specialty Segment

$108M50%